Haleon plc repurchased 102,272,727 shares from Pfizer for £315 million on March 21, 2024, as part of a £500 million share buyback plan for 2024. This buyback aligns with their capital allocation strategy and reduces Pfizer's stake in Haleon from 32% to approximately 22.6%.